LAS VEGAS – In patients with type 1 diabetes, adding a 1.8-mg daily dose of liraglutide to insulin significantly reduced hemoglobin A1c, mean blood glucose, body weight, carbohydrate intake, and C-reactive protein, in a randomized study.
The 72-patient study also showed that adding liraglutide (Victoza) significantly improved quality of life and reduced systolic blood pressure in the groups that were receiving higher doses of the medicine.
Naseem Miller/Frontline Medical NewsDr. Nitesh Kuhadiya
"Our findings have significant implications for the future treatment of type 1...